- ￥6500
- 齐源
- 127655
- 国产/进口
- 2025年07月15日
- PG
- 大鼠
- 小鼠
6 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 供应商：
齐源
- 库存：
999
- 靶点：
Ly-6G
- 级别：
Ly-6G Antibody
- 目录编号：
Ly-6G Antibody
- 克隆性：
单克隆
- 抗原来源：
大鼠
- 保质期：
Ly-6G Antibody
- 抗体英文名：
TotalSeq™-A0015 anti-mouse Ly-6G Antibody
- 抗体名：
Ly-6G Antibody
- 标记物：
Ly-6G Antibody
- 宿主：
大鼠
- 适应物种：
小鼠
- 免疫原：
Ly-6G Antibody
- 亚型：
Ly-6G Antibody
- 形态：
Ly-6G Antibody
- 应用范围：
PG
- 保存条件：
2-8℃
- 浓度：
0.5 mg/ml
- 规格：
10 µg
TotalSeq™-A0015 anti-mouse Ly-6G Antibody详细如下：
Description ：Lymphocyte antigen 6 complex, locus G (Ly-6G), a 21-25 kD GPI-anchored protein, isexpressed on the majority of myeloid cells in bone marrow and peripheral granulocytes.
Verified Reactivity ：Mouse
Antibody Type ：Monoclonal
Host Species ：Rat
Immunogen ：Ly-6G transfected EL-4J cell line
Formulation ：Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 1 mM EDTA.
Preparation ：The antibody was purified by chromatography and conjugated with TotalSeq™-A oligomer underoptimal conditions.
Concentration ：0.5 mg/ml
Storage & Handling ：The antibody solution should be stored undiluted between 2°C and 8°C. Do not freeze.
Application ：PG - Quality tested
Recommended Usage ：Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis and the oligomer sequence is confirmed by sequencing. TotalSeq™-A antibodies arecompatible with 10x Genomics Single Cell Gene Expression Solutions.
To maximize performance, it is strongly recommended that the reagent be titrated for eachapplication, and that you centrifuge the antibody dilution before adding to the cells at 14,000xg at 2- 8°C for 10 minutes. Carefully pipette out the liquid avoiding the bottom of the tube and add to thecell suspension. For Proteogenomics analysis, the suggested starting amount of this reagent fortitration is ≤ 1.0 µg per million cells in 100 µL volume. Refer to the corresponding TotalSeq™protocol for specific staining instructions.
Description ：Lymphocyte antigen 6 complex, locus G (Ly-6G), a 21-25 kD GPI-anchored protein, isexpressed on the majority of myeloid cells in bone marrow and peripheral granulocytes.
Verified Reactivity ：Mouse
Antibody Type ：Monoclonal
Host Species ：Rat
Immunogen ：Ly-6G transfected EL-4J cell line
Formulation ：Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 1 mM EDTA.
Preparation ：The antibody was purified by chromatography and conjugated with TotalSeq™-A oligomer underoptimal conditions.
Concentration ：0.5 mg/ml
Storage & Handling ：The antibody solution should be stored undiluted between 2°C and 8°C. Do not freeze.
Application ：PG - Quality tested
Recommended Usage ：Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis and the oligomer sequence is confirmed by sequencing. TotalSeq™-A antibodies arecompatible with 10x Genomics Single Cell Gene Expression Solutions.
To maximize performance, it is strongly recommended that the reagent be titrated for eachapplication, and that you centrifuge the antibody dilution before adding to the cells at 14,000xg at 2- 8°C for 10 minutes. Carefully pipette out the liquid avoiding the bottom of the tube and add to thecell suspension. For Proteogenomics analysis, the suggested starting amount of this reagent fortitration is ≤ 1.0 µg per million cells in 100 µL volume. Refer to the corresponding TotalSeq™protocol for specific staining instructions.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
Application References(PubMed link indicatesBioLegend citation)：
1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (FC)
2. Daley JM, et al. 2008. J. Leukocyte Biol. 83:1. (FC)
3. Dietlin TA, et al. 2007. J. Leukocyte Biol. 81:1205. (FC)
4. Daley J, et al. 2007. J. Leukocyte Biol. doi:10.1189. (Deplete) PubMed
5. Tadagavadi RK, et al. 2010. J. Immunol. 185:4904. PubMed
6. Sumagin R, et al. 2010. J. Immunol. 185:7057. PubMed
7. Guiducci C, et al. 2010. J. Exp Med. 207:2931. PubMed
8. Fujita M, et al. 2011. Cancer Res. 71:2664. PubMed
9. Van Leeuwen, et al. 2008. Arterioscler. Thromb. Vasc. Biol. 28:84. (IHC)
10. Kowanetz M, et al. 2010. P. Natl. Acad. Sci. USA 107:21248. [supplementary data] (IHC)
11. Esbona K, et al. 2016. Breast Cancer Res. 18:35. (IHC)
12. Wojtasiak M, et al. 2010. J. Gen. Virol. 91:2158. (FC, Deplete)
13. Jaeger BN, et al. 2012. J. Exp. Med. 209:565. (Deplete)
14. Wozniak KL, et al. 2012. BMC Immunol. 13:65 (FC, Deplete)
15. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
16. Ng LG, et al. 2011. J Invest. Dermatol. 131:2058. PubMed
17. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
18. McCartney-Francis, N, et al. 2014. J Leukoc. Biol. 96:917. PubMed
19. Her Z, et al. 2014. EMBO Mol. Med. 7:24. PubMed
20. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
21. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations：
1. Al-Rifai R, et al. 2022. Nat Commun. 13:6592. PubMed
2. Golomb SM, et al. 2020. Cell Rep. 33:108438. PubMed
3. Guldner IH, et al. 2020. Cell. 183(5):1234-1248.e25. PubMed
4. Guilliams M, et al. 2022. Cell. 185:379. PubMed
5. Guldner IH, et al. 2021. STAR Protocols. 2(2):100537. PubMed
6. Pisu D, et al. 2021. J Exp Med. 218:. PubMed
1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (FC)
2. Daley JM, et al. 2008. J. Leukocyte Biol. 83:1. (FC)
3. Dietlin TA, et al. 2007. J. Leukocyte Biol. 81:1205. (FC)
4. Daley J, et al. 2007. J. Leukocyte Biol. doi:10.1189. (Deplete) PubMed
5. Tadagavadi RK, et al. 2010. J. Immunol. 185:4904. PubMed
6. Sumagin R, et al. 2010. J. Immunol. 185:7057. PubMed
7. Guiducci C, et al. 2010. J. Exp Med. 207:2931. PubMed
8. Fujita M, et al. 2011. Cancer Res. 71:2664. PubMed
9. Van Leeuwen, et al. 2008. Arterioscler. Thromb. Vasc. Biol. 28:84. (IHC)
10. Kowanetz M, et al. 2010. P. Natl. Acad. Sci. USA 107:21248. [supplementary data] (IHC)
11. Esbona K, et al. 2016. Breast Cancer Res. 18:35. (IHC)
12. Wojtasiak M, et al. 2010. J. Gen. Virol. 91:2158. (FC, Deplete)
13. Jaeger BN, et al. 2012. J. Exp. Med. 209:565. (Deplete)
14. Wozniak KL, et al. 2012. BMC Immunol. 13:65 (FC, Deplete)
15. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
16. Ng LG, et al. 2011. J Invest. Dermatol. 131:2058. PubMed
17. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
18. McCartney-Francis, N, et al. 2014. J Leukoc. Biol. 96:917. PubMed
19. Her Z, et al. 2014. EMBO Mol. Med. 7:24. PubMed
20. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
21. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations：
1. Al-Rifai R, et al. 2022. Nat Commun. 13:6592. PubMed
2. Golomb SM, et al. 2020. Cell Rep. 33:108438. PubMed
3. Guldner IH, et al. 2020. Cell. 183(5):1234-1248.e25. PubMed
4. Guilliams M, et al. 2022. Cell. 185:379. PubMed
5. Guldner IH, et al. 2021. STAR Protocols. 2(2):100537. PubMed
6. Pisu D, et al. 2021. J Exp Med. 218:. PubMed
文献支持
TotalSeq™-A0015 抗小鼠 Ly-6G 抗体
￥6500
